| Literature DB >> 23950969 |
Juan Li1, Lijuan Wang, Margaret Ip, Mingjiao Sun, Jing Sun, Guoying Huang, Chuanqing Wang, Li Deng, Yuejie Zheng, Zhou Fu, Changcong Li, Yunxiao Shang, Changan Zhao, Sangjie Yu, Kaihu Yao, Yonghong Yang, Xuzhuang Shen.
Abstract
Detailed molecular analyses of Clonal Complex 59 (CC59) methicillin-resistant Staphylococcus aureus (MRSA) isolates from children in seven major cities across Mainland China were examined. A total of 110 CC59 isolates from invasive and non-invasive diseases were analyzed by multilocus sequence typing (MLST), Staphylococcus cassette chromosome mec (SCCmec) typing, staphylococcal protein A (spa) typing and pulsed-field gel electrophoresis (PFGE). Antibiotics susceptibilities, carriage of plasmids and 42 virulence genes and the expression of virulence factors were examined. ST59 (101/110, 91.8%) was the predominant sequence type (ST), while single locus variants (SLVs) belonging to ST338 (8/110, 7.3%) and ST375 (1/110, 0.9%) were obtained. Three SCCmec types were found, namely type III (2.7%), type IV (74.5%) and type V (22.7%). Seven spa types including t437, which accounted for 87.3%, were determined. Thirteen PFGE types were obtained. PFGE types A and B were the major types totally accounting for 81.8%. The dominant clone was ST59-t437-IVa (65.5%), followed by ST59-t437-V (14.5%). The positive rate of luks-PV and lukF-PV PVL encoding (pvl) gene was 55.5%. Plasmids were detected in 83.6% (92/110) of the strains. The plasmid size ranging from 23.4 kb to 50 kb was most prevalent which accounted for 83.7% (77/92). A significantly lower expression of hla was found in ST59-t437-IVa compared with ST59-t437-V. Among the 110 cases, 61.8% of the patients were less than 1 year old. A total of 90 cases (81.8%) were community-associated (CA) infections whereas 20 cases (18.2%) were hospital-associated (HA) infections. Out of the 110 patients, 36.4% (40/110) were diagnosed with invasive infectious diseases in which ST59-t437-IVa accounted for 67.5% (27/40). In brief, ST59-t437-IVa was proved as the dominant clone in CC59 MRSA strains. The carriage rate of pvl gene was high. CC59 MRSA could result in CA and HA infections. The majortiy of MRSA infection children were in young age.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23950969 PMCID: PMC3737374 DOI: 10.1371/journal.pone.0070602
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
PFGE, MLST, spa, SCCmec types and pvl results of CC59 MRSA isolates.
| PFGE pattern | No.(%) of isolates | MLST allele No. | MLST |
|
| SCC | No. of isolates |
|
| A | 45(40.9) | 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | IVa | 32 | 6 |
| 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | V | 5 | 1 | ||
| 19-23-15-2-19-20-15 | 59 | 04-20-17-25-34 | t441 | IVa | 1 | 0 | ||
| 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34-34 | t3523 | IVa | 2 | 2 | ||
| 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-20-17-25-34 | t3485 | IVa | 2 | 1 | ||
| 19-23-15-2-19-20-15 | 59 | NT | NT | III | 1 | 0 | ||
| 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | III | 1 | 0 | ||
| 19-23-15-2-19-20-42 | 375 | 15-12-16-02-24-24-24 | t2270 | IVa | 1 | 0 | ||
| B | 45(40.9) | 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | IVa | 27 | 25 |
| 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | V | 9 | 8 | ||
| 19-23-15-2-19-20-15 | 59 | 04-20-17-25-34 | t441 | IVa | 1 | 1 | ||
| 19-23-15-2-19-20-15 | 59 | 121-21-51-17-17-17-23-24 | t5350 | V | 1 | 1 | ||
| 19-23-15-48-19-20-15 | 338 | 04-20-17-20-17-25-34 | t437 | V | 4 | 3 | ||
| 19-23-15-48-19-20-15 | 338 | 04-20-17-20-17-25-34 | t437 | III | 1 | 1 | ||
| 19-23-15-48-19-20-15 | 338 | 04-02-17-20-17-25-34 | t3590 | V | 2 | 2 | ||
| C | 6(5.5) | 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | IVa | 4 | 0 |
| 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | IVc | 1 | 0 | ||
| 19-23-15-2-19-20-15 | 59 | 04-20-17-25-34 | t441 | IVa | 1 | 0 | ||
| D | 4(3.6) | 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | IVa | 3 | 3 |
| 19-23-15-2-19-20-15 | 59 | 04-20-17-25-34 | t441 | IVa | 1 | 1 | ||
| E | 2((1.8) | 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | IVa | 1 | 0 |
| 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | V | 1 | 0 | ||
| F | 1(0.9) | 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | IVa | 1 | 1 |
| G | 1(0.9) | 19-23-15-2-19-20-15 | 59 | 04-20-17-25-34 | t441 | IVa | 1 | 1 |
| H | 1(0.9) | 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34-34 | t3523 | IVa | 1 | 0 |
| I | 1(0.9) | 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | IVa | 1 | 1 |
| J | 1(0.9) | 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | IVa | 1 | 1 |
| K | 1(0.9) | 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | V | 1 | 1 |
| L | 1(0.9) | 19-23-15-2-19-20-15 | 59 | 04-20-17-20-17-25-34 | t437 | V | 1 | 0 |
| M | 1(0.9) | 19-23-15-48-19-20-15 | 338 | 04-20-17-20-17-25-34 | t437 | V | 1 | 1 |
Figure 1Thirteen representative pulsed-field gel electrophoresis patterns of the 110 CC59 MRSA strains.
Lanes marker, chromosomal DNA of Salmonella ser. Braenderup strain H9812 (27) was used as the size marker. (A) SZ12 MRSA ST59-t437-IVa; (B) G20 MRSA ST59-t437-IVa; (C) CQ6 MRSA ST59-t437-IVa; (D) BJ313 MRSA ST59-t437-IVa; (E) SH35 MRSA ST59-t437-V; (F) BJ57 MRSA ST59-t437-IVa; (G) SY183 MRSA ST59-t441-IVa; (H) BJ326 MRSA ST59-t3523-IVa; (I) SZ46 MRSA ST59-t437-IVa; (J) BJ787 MRSA ST59-t437-IVa; (K) SY76 MRSA ST59-t437-V; (L) BJ860 MRSA ST59-t437-V and (M). GZ1 MRSA ST338-t437-V.
Resistance to 16 antimicrobial agents of CC59 isolates in the major PFGE groups and predominant clones.
| Antimicrobialagents | CC59(n = 110) | PFGE A group(n = 45) | PFGE B group(n = 45) |
| ST59-t437-IVa(n = 72) | ST59-t437-V(n = 16) |
| ||||||||||
| % | % | % | % S | % R | % I | % S | % R | % I | % S | % R | % I | % S | % R | %I | |||
| Cefoxitin | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | ||
| Penicillin | 2.9 | 97.1 | 0.0 | 2.2 | 97.8 | 0.0 | 2.3 | 97.7 | 0.0 | 1.4 | 98.6 | 0.0 | 6.2 | 93.8 | 0.0 | ||
| Cefuroxime | 33.0 | 67.0 | 0.0 | 37.8 | 62.2 | 0.0 | 30.0 | 70.0 | 0.0 | 15.3 | 84.7 | 0.0 | 25.0 | 75.0 | 0.0 | ||
| Gentamicin | 78.6 | 21.4 | 0.0 | 84.4 | 15.6 | 0.0 | 81.8 | 18.2 | 0.0 | 79.2 | 20.8 | 0.0 | 62.5 | 37.5 | 0.0 | ||
| Chloramphenicol | 67.0 | 33.0 | 0.0 | 80.0 | 20.0 | 0.0 | 59.0 | 41.0 | 0.0 | <0.05 | 73.6 | 26.4 | 0.0 | 43.7 | 56.3 | 0.0 | <0.05 |
| Tetracycline | 36.0 | 44.6 | 19.4 | 44.4 | 35.6 | 20.0 | 29.5 | 52.3 | 18.2 | 10.6 | 83.3 | 6.1 | 6.2 | 93.8 | 0.0 | ||
| Sulfamethoxazole-trimethoprim | 89.3 | 10.7 | 0.0 | 95.6 | 4.4 | 0.0 | 86.4 | 13.6 | 0.0 | 84.7 | 15.3 | 0.0 | 87.5 | 12.5 | 0.0 | ||
| Rifampicin | 89.3 | 10.7 | 0.0 | 93.3 | 6.7 | 0.0 | 84.1 | 15.9 | 0.0 | 91.7 | 8.3 | 0.0 | 81.2 | 18.8 | 0.0 | ||
| Erythromycin | 0.9 | 99.1 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | ||
| Clindamycin | 6.4 | 93.6 | 0.0 | 8.9 | 91.1 | 0.0 | 2.3 | 97.7 | 0.0 | 4.2 | 95.8 | 0.0 | 6.2 | 93.8 | 0.0 | ||
| Ciprofloxacin | 75.7 | 11.7 | 12.6 | 68.9 | 8.9 | 22.2 | 81.8 | 11.4 | 6.8 | 47.2 | 38.9 | 13.9 | 87.5 | 12.5 | 0.0 | <0.05 | |
| Vancomycin | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | ||
| Linezolid | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | ||
| Tigecycline | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | ||
| Fusidic acid | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | ||
| Mupirocin | 98.2 | 1.8 | 0.0 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 98.6 | 1.4 | 0.0 | 100.0 | 0.0 | 0.0 | ||
S = susceptible.
R = resistant.
I = intermediate.
P* value: The resistant rate between PFGE A and B groups was compared.
P** value: The resistant rate between ST59-t437-IVa and ST59-t437-V was compared.